Previous 10 | Next 10 |
home / stock / repcf / repcf news
RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-gen...
Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, annou...
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE / October 27, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("Rep...
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC / ACCESSWIRE / October 12, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2)...
Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufacturing RepliCel signs an Option to License agreement related to a filed US patent applica...
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Com...
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) , (“RepliCel” or the “Company”) , a company developing...
Initial units delivered and first phase of functional testing nearly complete VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and ...
Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan VANCOUVER, BC / ACCESSWIRE / May 19, 2021 / RepliCel Li...
Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel's Skin Rejuvenation Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a c...
News, Short Squeeze, Breakout and More Instantly...
RepliCel Life Sciences Company Name:
REPCF Stock Symbol:
OTCMKTS Market:
RepliCel Life Sciences Website:
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developi...
Independent Testing Performed by Innovacell Demonstrates the DermaPrecise ™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency VANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliC...
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences ...